001060 JW중외제약
기본 정보
- 섹터: KOSPI:제약
- 시가총액: 5,984억원 (2026-06-30 기준)
- 첫 등장: 2026-06-29 (누적 1일)
- 태그: 매크로/IT소프트웨어 · 매크로/바이오헬스 · 제약 · 전문의약품 · 순환기 · 내분비 · AI
- 네이버 금융: 🔗
기업개요
- 동사는 1945년 ‘조선중외제약소’로 출범해 1953년 ‘대한중외제약 주식회사’로 법인을 설립하고, 1976년 기업공개를 통해 유가증권시장에 상장하였음.
- 2019년 베트남 Euvipharm社를 100% 인수하며 이머징 시장으로 사업영역을 확장하였음.
- 동사는 의약품의 연구, 개발, 제조, 판매를 주요 사업으로 하며, 리바로, 헴리브라, 트루패스, 악템라 등 오리지널 파이프라인과 3세대 3챔버 영양수액 위너프를 보유하고 있음.
출처: 네이버증권 종목분석 (WiseReport)
일자별 등장 (최신 위, 누적)
| 일자 | 전일 종가 | 종가 | 등락률 | 시간외 | vol | 색깔 | smart | 외 | 연 | 금투 | 투 | 개 | 그외 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-14 | 28,950 | 28,550 | 🔵 -1.38% | -1.03%p | ×1.8 | 🔻 개인 | -10.0억 | -9.8 | -0.2 | +0.1 | -0.0 | +6.8 | +3.1 |
| 2026-08-13 | 30,000 | 28,950 | 🔵 -3.50% | +1.50%p | ×2.7 | 🔻 개인 | -15.8억 | -19.0 | +3.2 | -0.1 | +0.0 | +17.1 | -1.2 |
| 2026-08-12 | 29,550 | 30,000 | 🔴 +1.52% | +0.00%p | ×13.4 | 🔻 개인 | -35.4억 | -42.3 | +6.8 | +0.1 | +0.1 | +31.1 | +4.3 |
| 2026-08-11 | 25,700 | 29,550 | ➕ 🔴 +14.98% | +12.84%p ⚡ | ×1.1 | 🟢 외인 | +0.4억 | +0.4 | +0.0 | +0.1 | -0.0 | -0.5 | +0.0 |
| 2026-08-10 | 24,900 | 25,700 | 🔴 +3.21% | +0.00%p | ×1.0 | 🟢 외인 | +0.7억 | +1.1 | -0.5 | +0.0 | +0.0 | -0.6 | -0.1 |
| 2026-08-07 | 24,650 | 24,900 | 🔴 +1.01% | +0.00%p | ×0.8 | 🟢 외인 | +2.3억 | +2.3 | +0.0 | -0.0 | +0.0 | -2.3 | +0.0 |
| 2026-08-06 | 24,200 | 24,650 | 🔴 +1.86% | +0.21%p | ×1.0 | 🟢 외인 | +0.2억 | +0.2 | +0.1 | +0.1 | +0.0 | +0.1 | -0.5 |
| 2026-08-05 | 24,150 | 24,200 | 🔴 +0.21% | -0.62%p | ×0.8 | 🟢 외인 | +1.2억 | +1.2 | +0.0 | -0.0 | -0.0 | -1.1 | -0.1 |
| 2026-08-04 | 23,050 | 24,150 | 🔴 +4.77% | -0.22%p | ×0.9 | 🟢 외인 | +1.6억 | +1.6 | +0.0 | -0.1 | +0.0 | -1.5 | +0.1 |
| 2026-08-03 | 23,500 | 23,050 | 🔵 -1.91% | -0.63%p | ×0.6 | 🔻 개인 | -0.8억 | -0.8 | +0.0 | +0.1 | +0.0 | +0.6 | +0.1 |
| 2026-07-31 | 22,500 | 23,500 | 🔴 +4.44% | +0.00%p | ×0.8 | 🟢 외인 | +0.3억 | +0.3 | -0.2 | -0.2 | +0.2 | -0.1 | +0.0 |
| 2026-07-30 | 22,100 | 22,500 | 🔴 +1.81% | -0.45%p | ×1.0 | 🟢 외인 | +4.7억 | +4.7 | +0.0 | -0.2 | +0.0 | -4.5 | +0.0 |
| 2026-07-29 | 23,000 | 22,100 | 🔵 -3.91% | +0.44%p | ×2.1 | 🟢 외인 | +1.3억 | +1.4 | -0.0 | +0.1 | -0.0 | -0.9 | -0.5 |
| 2026-07-28 | 24,100 | 23,000 | 🔵 -4.56% | -0.41%p | ×1.3 | 🔻 개인 | -2.1억 | -2.0 | -0.0 | +0.1 | -0.0 | +1.9 | +0.0 |
| 2026-07-27 | 24,000 | 24,100 | 🔴 +0.42% | +0.42%p | ×0.4 | 🔻 개인 | -0.8억 | -0.8 | +0.0 | -0.0 | +0.0 | +0.8 | +0.0 |
| 2026-07-24 | 24,100 | 24,000 | 🔵 -0.41% | -0.62%p | ×1.2 | 🟢 외인 | +0.9억 | +1.1 | +0.0 | +0.1 | -0.2 | -0.8 | -0.2 |
| 2026-07-23 | 23,500 | 24,100 | 🔴 +2.55% | +0.00%p | ×0.9 | 🟢 외인 | +3.0억 | +3.5 | -0.9 | -0.0 | +0.4 | -3.0 | +0.0 |
| 2026-07-22 | 23,750 | 23,500 | 🔵 -1.05% | +0.42%p | ×0.7 | 🔻 개인 | -0.9억 | -0.9 | +0.0 | -0.0 | -0.0 | +0.9 | +0.0 |
| 2026-07-21 | 23,700 | 23,750 | 🔴 +0.21% | +0.21%p | ×0.7 | 🟢 외인 | +0.6억 | +0.6 | +0.0 | -0.1 | +0.0 | -0.5 | +0.0 |
| 2026-07-20 | 24,300 | 23,700 | 🔵 -2.47% | +1.44%p | ×0.7 | 🔻 개인 | -1.9억 | -1.9 | +0.0 | +0.0 | +0.0 | +1.9 | +0.0 |
| 2026-07-16 | 24,350 | 24,300 | 🔵 -0.21% | +0.20%p | ×0.7 | 🔻 개인 | -0.6억 | -0.6 | +0.0 | +0.0 | +0.0 | +0.7 | -0.1 |
| 2026-07-15 | 23,750 | 24,350 | 🔴 +2.53% | +0.42%p | ×0.5 | 🟢 외인 | +2.3억 | +2.3 | +0.0 | -0.1 | +0.0 | -2.2 | -0.0 |
| 2026-07-14 | 24,050 | 23,750 | 🔵 -1.25% | +1.24%p | ×1.4 | 🔻 개인 | -1.3억 | -1.8 | +0.4 | -0.0 | +0.0 | +2.0 | -0.7 |
| 2026-07-13 | 25,000 | 24,050 | 🔵 -3.80% | +0.20%p | ×0.6 | 🔻 개인 | -0.7억 | -0.7 | -0.0 | +0.0 | +0.0 | +0.7 | +0.0 |
| 2026-07-10 | 23,600 | 25,000 | 🔴 +5.93% | +0.00%p | ×0.7 | 🟢 외인 | +3.9억 | +3.8 | +0.0 | -0.2 | +0.1 | -3.6 | -0.1 |
| 2026-07-09 | 23,750 | 23,600 | 🔵 -0.63% | -0.42%p | ×1.0 | 🟢 외인 | +4.4억 | +4.1 | +0.2 | +0.0 | +0.0 | -4.5 | +0.1 |
| 2026-07-08 | 25,200 | 23,750 | 🔵 -5.75% | -1.38%p | ×0.7 | 🟢 외인 | +3.0억 | +3.0 | +0.0 | -0.4 | -0.0 | -2.5 | -0.1 |
| 2026-07-07 | 25,300 | 25,200 | 🔵 -0.40% | -0.60%p | ×0.8 | 🟢 외인 | +1.1억 | +1.1 | +0.0 | +0.1 | +0.0 | -1.2 | +0.0 |
| 2026-07-06 | 25,900 | 25,300 | 🔵 -2.32% | +0.00%p | ×0.5 | 🔻 개인 | +0.0억 | +0.0 | +0.0 | +0.0 | +0.0 | +0.5 | -0.6 |
| 2026-07-03 | 25,750 | 25,900 | 🔴 +0.39% | +0.00%p | ×1.0 | 🟢 외인 | +3.1억 | +3.1 | +0.0 | +0.0 | -0.0 | -3.1 | -0.1 |
| 2026-07-02 | 26,000 | 25,750 | 🔵 -0.96% | -0.19%p | ×0.5 | 🔻 개인 | -1.2억 | -1.2 | +0.0 | +0.1 | +0.0 | +1.0 | +0.1 |
| 2026-07-01 | 25,650 | 26,000 | 🔴 +1.36% | +0.00%p | ×0.7 | ⚫ 그외 | +1.4억 | -1.1 | +2.5 | +0.0 | +0.0 | -4.4 | +3.0 |
| 2026-06-30 | 26,300 | 25,650 | 🔵 -2.47% | -0.19%p | ×0.5 | 🔻 개인 | -2.0억 | -2.4 | +0.3 | -0.1 | +0.1 | +2.0 | +0.1 |
| 2026-06-29 | 23,700 | 26,300 | 🔴 +10.97% | -0.21%p | ×1.2 | 🟢 외인 | +10.4억 | +11.0 | -0.6 | +0.0 | +0.0 | -10.2 | -0.2 |
| 2026-06-26 | 25,000 | 23,700 | 🔵 -5.20% | -1.60%p | ×1.5 | 🟢 외인 | +7.2억 | +7.8 | -0.6 | +0.1 | +0.0 | -8.3 | +1.0 |
| 2026-06-25 | 25,900 | 25,000 | 🔵 -3.47% | -0.96%p | ×0.6 | 🟢 외인 | +0.3억 | +0.5 | +0.0 | +0.1 | -0.2 | -0.6 | +0.1 |
| 2026-06-24 | 24,550 | 25,900 | 🔴 +5.50% | -0.20%p | ×0.7 | 🟢 외인 | +2.4억 | +2.4 | +0.0 | +0.1 | -0.0 | -2.5 | +0.0 |
| 2026-06-23 | 25,650 | 24,550 | 🔵 -4.29% | -1.76%p | ×1.6 | 🟢 외인 | +2.8억 | +2.3 | +0.5 | +0.1 | -3.1 | +0.2 | |
| 2026-06-22 | 26,850 | 25,650 | 🔵 -4.47% | -0.19%p | ×1.0 | 🟢 외인 | +4.7억 | +4.7 | +0.0 | -0.2 | -1.4 | -3.2 | |
| 2026-06-19 | 27,050 | 26,850 | 🔵 -0.74% | +0.55%p | ×1.3 | 🟦 연기금 | +4.5억 | +1.1 | +3.4 | -0.2 | -4.0 | -0.3 | |
| 2026-06-18 | 28,150 | 27,050 | 🔵 -3.91% | -0.71%p | ×0.6 | 🟦 연기금 | +0.6억 | -1.6 | +2.2 | -0.2 | -1.0 | +0.6 | |
| 2026-06-17 | 27,300 | 28,150 | 🔴 +3.11% | +0.91%p | ×1.0 | 🟢 외인 | +1.7억 | +2.0 | -0.3 | -0.1 | -1.6 | +0.0 | |
| 2026-06-16 | 28,200 | 27,300 | 🔵 -3.19% | +0.18%p | ×0.7 | 🟢 외인 | +1.1억 | +0.8 | +0.3 | -0.1 | -0.8 | -0.1 | |
| 2026-06-15 | 26,900 | 28,200 | 🔴 +4.83% | +0.55%p | ×1.4 | 🔻 개인 | -9.5억 | -9.5 | +0.0 | -0.2 | +9.1 | +0.6 | |
| 2026-06-12 | 26,750 | 26,900 | 🔴 +0.56% | -0.56%p | ×0.8 | 🟡 금투 | +0.0억 | +0.0 | +0.0 | +0.2 | -0.2 | -0.1 | |
| 2026-06-11 | 25,900 | 26,750 | 🔴 +3.28% | +0.96%p | ×0.8 | ⚫ 그외 | -0.8억 | -0.3 | -0.6 | +0.1 | -0.4 | +1.2 | |
| 2026-06-10 | 26,150 | 25,900 | 🔵 -0.96% | -1.72%p | ×0.5 | 🔻 개인 | -0.5억 | -0.8 | +0.3 | +0.1 | +0.4 | -0.0 | |
| 2026-06-09 | 24,250 | 26,150 | 🔴 +7.84% | +0.21%p | ×0.8 | 🟢 외인 | +2.9억 | +3.1 | -0.2 | -0.0 | -2.6 | -0.2 | |
| 2026-06-08 | 26,000 | 24,250 | 🔵 -6.73% | -0.77%p | ×1.2 | 🟢 외인 | +5.6억 | +5.9 | -0.2 | +0.1 | -6.7 | +1.0 | |
| 2026-06-05 | 26,000 | 26,000 | ⚪ +0.00% | +0.00%p | ×0.8 | 🟡 금투 | -0.4억 | -0.4 | +0.0 | +0.2 | +0.2 | +0.0 | |
| 2026-06-04 | 27,050 | 26,000 | 🔵 -3.88% | -0.55%p | ×1.1 | ⚫ 그외 | +0.3억 | +0.3 | +0.0 | +0.1 | -4.5 | +4.0 | |
| 2026-06-02 | 27,100 | 27,050 | 🔵 -0.18% | +0.56%p | ×0.9 | 🟢 외인 | +5.4억 | +5.7 | -0.3 | +0.2 | -5.8 | +0.2 | |
| 2026-06-01 | 27,800 | 27,100 | 🔵 -2.52% | +0.18%p | ×1.4 | 🟢 외인 | +4.7억 | +4.7 | +0.0 | -0.1 | -4.6 | +0.0 | |
| 2026-05-29 | 28,350 | 27,800 | 🔵 -1.94% | +0.00%p | ×0.8 | 🟢 외인 | +2.0억 | +3.4 | -1.4 | -0.3 | -2.7 | +1.0 | |
| 2026-05-28 | 29,500 | 28,350 | 🔵 -3.90% | -0.34%p | ×0.9 | ⚫ 그외 | -0.4억 | -0.4 | +0.0 | +0.1 | -1.3 | +1.6 | |
| 2026-05-27 | 29,400 | 29,500 | 🔴 +0.34% | +0.85%p | ×0.9 | 🟢 외인 | +1.2억 | +1.2 | +0.0 | -0.7 | +0.2 | -0.7 | |
| 2026-05-26 | 30,050 | 29,400 | 🔵 -2.16% | +0.17%p | ×0.7 | 🔻 개인 | -8.4억 | -8.4 | +0.0 | -0.1 | +7.0 | +1.6 | |
| 2026-05-22 | 28,850 | 30,050 | 🔴 +4.16% | +0.35%p | ×0.6 | 🟢 외인 | +7.4억 | +5.9 | +1.5 | +0.0 | -7.3 | -0.1 |
일자별 사유 (최신 위)
2026-08-11
- 사유: 통풍 신약 에파미뉴라드 글로벌 3상 성공, 내년 국내허가 추진
- 섹터 컨텍스트: KOSPI:제약 (smart +1,430억)
- 매크로 원인: 제약·바이오 개별 임상·허가 호재 잇따르며 급등 (통풍신약 3상 성공, 이상지질혈증제 허가 등) (높음)
2026-06-29
- 사유: —
- 섹터 컨텍스트: KOSPI:제약 (smart +895억)
- 매크로 원인: 반도체 쏠림 차익실현 후 제약·바이오로 순환매 유입 + 국민성장펀드 기대·바이오USA 훈풍에 동반 급등 (보통)